Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AN2-502998 · 1 trial · 1 indication
Incidence, relatedness, and severity of adverse events
Incidence of physical exam abnormalities
Incidence of changes in blood pressure, pulse, respiratory rate, and temperature
Incidence of changes in 12-lead ECG parameters from baseline
Incidence of changes in clinical laboratory measurements from baseline
Incidence, relatedness, and severity of adverse events
Incidence of physical exam abnormalities
Incidence of changes in blood pressure, pulse, respiratory rate, and temperature
Incidence of changes in 12-lead ECG parameters from baseline
Incidence of changes in clinical laboratory measurements from baseline
Determination of the maximum plasma concentration (Cmax)
Determination the time to maximum plasma concentration (Tmax)
Determine the apparent terminal half-life (t½)
Area under plasma concentration-time curve from zero to a designated dosing interval
Apparent plasma clearance of drug after extravascular administration CL/F
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will be randomized in a 3:1 ratio to receive a single dose of either AN2-502998 or placebo. |
| Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants will be randomized in a 3:1 ratio to receive multiple doses of either AN2-502998 or placebo. |
| Name | Type | Description |
|---|---|---|
| AN2-502998 | DRUG | Oral Capsule |
| Placebo | DRUG | Oral Capsule |
Inclusion Criteria: 1. Male or female aged 18 to 55 years, inclusive, at Screening 2. Willing and able to provide written informed consent 3. Willing and able to comply with all trial assessments and adhere to the protocol schedule 4. BMI between ≥18 and \<32 kg/m2 (inclusive); BMI is calculated as...
AN2-502998 is an investigational small molecule being developed by AN2 Therapeutics, Inc. (NASDAQ: ANTX). It is currently in Phase 1 clinical development, having completed a first-in-human trial in healthy volunteers. The drug is being studied for its safety, tolerability, and pharmacokinetics.
AN2-502998 is being studied in healthy volunteers as part of a first-in-human Phase 1 trial. The trial is designed to evaluate the drug's safety, tolerability, and how it is processed by the body. Its intended therapeutic use has not been specified in the available information.
AN2-502998 is being developed by AN2 Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ANTX. The company is conducting clinical trials to evaluate this investigational small molecule.
AN2-502998 is in Phase 1 clinical development. A first-in-human trial of the oral drug has been completed. The drug is investigational and has not been approved by regulatory authorities.
AN2-502998 has one completed Phase 1 clinical trial, registered as NCT07024589, titled "First-in-Human Trial of Oral AN2-502998." The trial enrolled 72 healthy volunteers in Australia and was randomized, double-blind, and controlled.
No alternative names for AN2-502998 have been disclosed. It is identified solely by its code name AN2-502998 in clinical trial registrations and company communications.